ELF2

Across TCGA pan-cancer cohorts, ELF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ELF2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ELF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ELF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where ELF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.482	0.309	.003	51	view →
CCRCC	DFS	Quartile	III,IV	0.905	0.341	.001	24	view →
HNSC	OS	Median	All	0.775	0.932	.002	24	view →
UCEC	OS	Quartile	II,III,IV	0.484	1.000	.025	12	view →
LUAD	DFS	Median	II,III,IV	0.716	0.929	.003	10	view →
GBM	OS	Tertile	All	0.743	0.950	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ELF2–PDAC (DFS)

Open the PDAC breakdown →